Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index; 9 of the 13 sources its claims cite were checked for support.
Abstract
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. METHODS: In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle-formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. RESULTS: A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. CONCLUSIONS: A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.).
Overview
CoChat Summary
TL;DR
In a phase 2/3 multinational trial, two 30-μg doses of BNT162b2 given 21 days apart were 95% effective against laboratory-confirmed Covid-19 in participants 16 years of age or older. The vaccine’s safety profile was characterized mainly by short-term, mild-to-moderate local and systemic reactions, with serious adverse events similar between vaccine and placebo groups.
Key findings
- Among 43,548 randomized participants, 43,448 received injections: 21,720 BNT162b2 and 21,728 placebo. In the efficacy population without prior infection, there were 8 Covid-19 cases in vaccine recipients vs. 162 in placebo recipients, corresponding to 95.0% vaccine efficacy (95% CI, 90.3 to 97.6).
- Among participants with or without evidence of prior SARS-CoV-2 infection, 9 Covid-19 cases occurred in vaccine recipients vs. 169 in placebo recipients, for 94.6% efficacy (95% CI, 89.9 to 97.3).
- Of 10 severe Covid-19 cases with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. Between the first and second doses, vaccine efficacy was 52% (95% CI, 29.5 to 68.4).
- Reactogenicity was mostly mild-to-moderate; common events included injection-site pain, fatigue, and headache. Serious adverse events occurred in 0.6% of vaccine recipients and 0.5% of placebo recipients.
Methods
- Ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial; participants 16 years of age or older were randomly assigned 1:1 to receive two doses, 21 days apart, of 30 μg BNT162b2 or saline placebo.
- Primary end points were efficacy against laboratory-confirmed Covid-19 and safety. Efficacy was estimated as 100×(1−IRR), with a Bayesian beta-binomial model; safety analyses were descriptive.
- The main safety subset included 37,706 participants with a median of at least 2 months of safety data after the second dose; the reactogenicity subset included 8,183 participants.
Limitations
- The paper states that with approximately 19,000 participants per group and a median follow-up of 2 months after the second dose, the trial is not large enough to detect less common adverse events reliably; longer-term adverse events and durability of protection remain to be determined.
- The paper states that ethical and practical barriers prevent following placebo recipients for the planned 2 years once the vaccine is approved and recommended, and that the data do not address whether vaccination prevents asymptomatic infection or establish a correlate of protection.
- The paper states that it does not address prevention of Covid-19 in younger adolescents, children, or pregnant women; the text also makes evident that the main safety subset was 49% female, 83% White, 9% Black or African American, 28% Hispanic or Latinx, with a median age of 52 years, which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 1 Not valid · 3 Not checked · 59 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The favorable safety profile observed during phase 1 testing of BNT162b24,8 was confirmed in the phase 2/3 portion of the trial.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Partly supportedcites [4] Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. DOI: 10.1056/NEJMoa2027906. PMC7583697 33053279 sourceExperimental — accuracy not yet measured
The Introduction reports safety data from the Phase 1 portion of the trial, and the Discussion says those data helped select BNT162b2 for Phase 2/3 evaluation. The Discussion describes Phase 2/3 safety assessment as ongoing; this paper does not report Phase 2/3 results confirming the Phase 1 safety profile. No page numbers are available in our copy. (LLM, conf=0.90)
- Partly supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. sourceExperimental — accuracy not yet measured
The Safety and tolerability section reports no related serious adverse events, grade-4 reactions, or withdrawals due to related adverse events in this phase-I/II study, supporting the description of a favorable early safety profile. The paper does not report phase-2/3 safety results confirming that profile; its Clinical trial design section identifies the presented data as coming from a phase-I/II trial. (LLM, conf=0.85)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“In addition, the reactogenicity profile of BNT162b2 represented mainly short-term local (i.e., injection site) and systemic responses.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Abstract > Conclusions
What the sources say
- Supportedcites [8] Sahin U, Muik A, Vogler I, et al. BNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans. December 11, 2020 (https://www.medrxiv.org/content/10.1101/2020.12.09.20245175v1). preprint. source
The Safety and tolerability section reports local reactions, predominantly injection-site pain, and systemic reactions including fatigue and headache. It says reactions began within 24 hours and mostly resolved within two or three days, supporting the description of mainly short-term responses. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Severe fatigue was observed in approximately 4% of BNT162b2 recipients, which is higher than that observed in recipients of some vaccines recommended for older adults.12”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Could not verifycites [12] Cowling BJ, Perera RAPM, Valkenburg SA, et al. Comparative immunogenicity of several enhanced influenza vaccine options for older adults: a randomized, controlled trial. Clin Infect Dis 2020; 71: 1704- 1714. 31828291 PMC7289658 sourceExperimental — accuracy not yet measured
The Results section reports local reactions and serious adverse events after influenza vaccination, but gives no rate of severe fatigue. Searches for severe fatigue and systemic reactions found no passage in our copy that supports the comparison with BNT162b2 recipients. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
Every source the paper cites for this claim was checked and supports it.
In the paper
“The cumulative incidence of Covid-19 cases over time among placebo and vaccine recipients begins to diverge by 12 days after the first dose, 7 days after the estimated median viral incubation period of 5 days,10 indicating the early onset of a partially protective effect of immunization.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Discussion
What the sources say
- Supportedcites [10] Lauer SA, Grantz KH, Bi Q, et al. The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med 2020; 172: 577- 582. 32150748 PMC7081172 source
The Discussion reports a median incubation period of 5.2 days, supporting the approximately five-day estimate to which the citation is attached. The vaccine–placebo divergence is not attributed to this source. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“No deaths were considered by the investigators to be related to the vaccine or placebo.”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Adverse Events
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
26 more claims
Create a free account to see all 69 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 28
- Probably not a substantial claim. 12
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“This is notable, as these titers were associated with 95% protection from COVID-19 in phase 3 trials (44, 46, 48, 49).”
From mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection (2021) · cites this paper as [46]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“However, both the Oxford-AstraZeneca and Pfizer vaccines give substantial initial efficacy after a single dose of vaccine against parental strains (∼76 and 89%, respectively)”
From Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera (2021) · cites this paper as Polack et al., 2020
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“Most large Covid-19 vaccine efficacy trials have reported notably increased vaccine efficacy against severe versus mild to moderate disease.4–7”
From Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant (2021) · cites this paper as [5]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The primary endpoints of the COVID-19 mRNA vaccine clinical trials were a non-severe infection with at least one clinical symptom [31,32].”
From Relative risk reduction: Misinformative measure in clinical trials and COVID-19 vaccine efficacy (2022) · cites this paper as [32]
Experimental — accuracy not yet measured
84 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“although fatigue and headache were also reported by many placebo recipients”
§ Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine > Results > Safety
“23% and 24%, respectively, after the second dose, among younger vaccine recipients; 17% and 14% among older recipients”
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Lauer, S. A., Grantz, K. H., Bi, Q., Jones, F. K., Zheng, Q., Meredith, H. R., Azman, A. S., Reich, N. G., & Lessler, J. (2020) · Annals of Internal Medicine · doi:10.7326/m20-0504 · Cited by 5,970
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03653-6 · Cited by 919
Self-citationBNT162b2 induces SARS-CoV-2-neutralising antibodies and T cells in humans
Sahin, U., Muik, A., Vogler, I., Derhovanessian, E., Kranz, L. M., Vormehr, M., Quandt, J., Bidmon, N., Ulges, A., Baum, A., et al. (2020) · doi:10.1101/2020.12.09.20245175 · Cited by 914
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Cowling, B. J., Perera, R. A. P. M., Valkenburg, S. A., Leung, N. H. L., Iuliano, A. D., Tam, Y. H., Wong, J. H. F., Fang, V. J., Li, A. P. Y., So, H. C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciz1034 · Cited by 110
Cited by
Items 14,001–14,100 of 15,747
Boppana, S. H., Luke, N., Karuchola, S., Udaikumar, J., & Mintz, C. D. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18040455
“Given the real-world demonstration of safe and effective mRNA vaccines during the COVID-19 pandemic [71,72], it is reasonable to expect broader application of mRNA-based therapeutics across medicine, including hepatology.”
Volk, A., Covini-Souris, C., Kuehnel, D., de Mey, C., Römisch, J., & Schmidt, T. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.08.13.456066
Theories of Contagion and Cancer
Fuller, J. (2025) · Oxford University Press eBooks · doi:10.1093/9780190066178.003.0003
Serosurvey of SARS-COV-2 at a large public universityPreprint
Hou, C., Williams, S., Taylor, K., Boyle, V., Bobbett, B., Kouvetakis, J., Nguyen, K., McDonald, A., Harris, V. K., Nussle, B., et al. (2023) · medRxiv · doi:10.1101/2023.02.05.23285494
Kastl, A., Weaver, K. N., Zhang, X., et al. (2024) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1002/jpn3.12142
Kolben, Y., Finkelshtein, E., Code Pharma, T. N., Naftali, E., Code Pharma, T. N., Kenig, A., Kessler, A., Cardoso, F., Lisovoder, N., Code Pharma, T. N., et al. (2022) · Discoveries · doi:10.15190/d.2022.17
“DISCOVERIES 2022, Oct-Dec; 10(4): e158 DOI: 10.”
(2021) · doi:10.1101/2021.09.21.21263883
“The modeled EDIII constructs for the serotypes (1-4) showing the structural alignment with the template, Ramachandran plot analysis and ProSA energy analysis (A-D).”
BackgroundThe First Ethiopian Case Report of Post-Covid-19 Vaccine Associated Guillain-Barre Syndrome
Demissie, Z. (2022) · Neurons and Neurological Disorders · doi:10.58489/2836-8851/002
Kavalibasappla, A., Nagendra, K., Lingaraj, P. H., Koppad, R., Mandi, M., Rajanna, D., & Mallikarjunappa, S. K. G. (2023) · Asian Journal of Medical Sciences · doi:10.3126/ajms.v14i1.46425
Hederman, A. P., Brookes, H. M., Natarajan, H., et al. (2024) · medRxiv · doi:10.1101/2024.09.12.24313591
The Role of Vaccines in Complementing Antiviral Treatments and Reducing Viral Spread
Akhtar, F., & Gul, S. (2025) · IGI Global eBooks · doi:10.4018/979-8-3693-9276-8.ch001
Measuring the efficacy of a vaccine during an epidemicPreprint
Scala, A., & Cavallo, P. (2023) · doi:10.32388/0oot92
Thrombocytopenia as an Emerging Adverse Event Associated with COVID-19/SARS-CoV2 Vaccination
Welker, J. A., Crowe, A., & Hassan, W. (2022) · Journal of Pharmaceutical Research International · doi:10.9734/jpri/2022/v34i54b7239
Engineered Soluble ACE2 Protein and SARS-CoV-2 Variants of Concern (VOCs)
Leowattana, W. (2022) · Coronaviruses · doi:10.2174/2666796703666220520101225
Insights from assessment for arrhythmia after CoViD-19 vaccination among Indians
Sunita, S., Negi, M. B., Lal, M., Kumar, C., & Kumar, M. (2024) · Bioinformation · doi:10.6026/973206300200430
Taymur, B. D., & Toklucu, G. (2026) · Journal of Health Sciences and Medicine · doi:10.32322/jhsm.1883733
Syed, A. A., Eqbal, F., Shamsi, H. R., Syed, A. R. S., Zakir, S. J., Fawzy, M., & Khan, K. S. (2024) · Medicina de Familia SEMERGEN · doi:10.1016/j.semerg.2024.102343 · Cited by 1
Sala, L. L., Rispoli, F., Bianchi, B., et al. (2022) · La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine · doi:10.23736/s1825-859x.22.00156-6
Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults
Liu, S. T. H., González‐Domínguez, I., Martínez-Pérez, A., et al. (2026) · Vaccine · doi:10.1016/j.vaccine.2026.128870
Naturopathic Medicine on the Frontline of the COVID-19 Pandemic
Halldorson, C. (2021) · CAND Journal · doi:10.54434/candj.94
Qiao, N., Ishikawa, J., Yasui, F., Sano, K., Miyakawa, K., Hayashi, A., Amiry, A. F., Haonan, L., Xueyang, Z., Sato, T., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2025.12.24.696305
An overview of the mRNA applications and their therapeutic functions in clinical development
Ramakrishnaiah, T. N., Srikar, K. S., Deb, A., Ahmed, K. S., Chandraghatgi, R. R., Sarin, Y., Roopini, K., & Rajashekara, S. (2026) · Next research. · doi:10.1016/j.nexres.2026.101413
Khan, I., Ravindran, R. K., Kang, H., McReynolds, C. B., Sanghar, G. K., Chang, W. C., Ramasamy, S., Kolloli, A., Kumar, R., Subbian, S., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1987647/v1
CME: Hypertonie und die COVID-19-Pandemie: Was in der medizinischen Praxis zu beachten ist
Wuerzner, G., & Waeber, B. (2021) · Praxis · doi:10.1024/1661-8157/a003635
New Applications for the Kinetic Exclusion Assay (KinExA)
Smith, M. H. (2021) · doi:10.18122/td.1787.boisestate
Weinberg, A. R., Caeg, C. O., DePalma, R., et al. (2023) · Clinical Transplantation · doi:10.1111/ctr.15072
“6,7 8 However, one must consider potential decreased immune response to vaccines due to the immunocompromised state of CKD patients as well as that of renal transplant recipients.”
BackgroundEl-Kafrawy, S. A., Othman, N. A., Zeyadi, M., El-Daly, M. M., & Azhar, E. I. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1904701
Covid-19 Vaccinations and Menstrual Cycle Alteration
Hussain, S., Chaturvedi, V., Singh, M., et al. (2023) · Bioequivalence & Bioavailability International Journal · doi:10.23880/beba-16000182
Ooyama, K., Kaneko, N., Kitazumi, Y., et al. (2022) · Nihon Toseki Igakkai Zasshi · doi:10.4009/jsdt.55.589
Valenzi, N. (2023) · Western Journal of Emergency Medicine · doi:10.5811/westjem.62602
Impfstoffentwicklung zur Prävention von COVID-19 bei Jugendlichen
Augustin, M., Hallek, M. J., Nitschmann, S., et al. (2021) · Der Internist · doi:10.1007/s00108-021-01195-7
“Dies muss im direkten Vergleich zu den errechneten Impfeffektivitäten des jeweiligen Impfstoffs für Erwachsene berücksichtigt werden [3, 4] und unterstreicht das”
BackgroundAbou-Saleh, H., Abo-Halawa, B. Y., Younes, S. N., et al. (2022) · medRxiv · doi:10.1101/2022.05.08.22274817
COVID ‐19 Vaccination and Infection in Myasthenia Gravis: A Longitudinal Patient Survey
Li, Y., Muppidi, S., Unnithan, S., Al‐Khalidi, H. R., Masterson, S., Huff, W., Juel, V. C., Guptill, J. T., & Raja, S. M. (2025) · Muscle & Nerve · doi:10.1002/mus.28466
Anscombe, C., Lissauer, S., Thole, H., Rylance, J., Dula, D., Menyere, M., Kutambe, B. M., van der Veer, C., Phiri, T., Banda, N. P. K., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609247
Ata, I., Rafique, A., Ameer, H., Fayyaz, A., Sidddiqui, A., & Anwar, A. (2023) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs2023175564
Novel progression on clinical therapy of COVID-19: Western and Traditional Chinese Medicines
Xiong, Y., Li, Y., & Xing, F. (2025) · Exploration of Drug Science · doi:10.37349/eds.2025.1008102
Modeling and Forecast of COVID-19 Vaccinations Population Size in China: A Non-Clinical StudyPreprint
Du, W., Hua, F., Xu, S., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-729132/v1
Siniscalchi, C., Imbalzano, E., Basaglia, M., Cerundolo, N., Meschi, T., Prati, B., Parise, A., Nouvenne, A., & Micco, P. D. (2026) · Vaccines · doi:10.3390/vaccines14070611
The Silver Lining of the COVID-19 Pandemic: Fast-Tracked Vaccine Production and Approval
Mandala, W. L. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.107254 · Cited by 1
Campos-Murguía, A., Román-Calleja, B. M., González-Regueiro, J. A., de León, I. H.-D., Solís-Ortega, A. A., Flores-García, N. C., García-Juárez, I., Ruiz‐Margáin, A., & Macías‐Rodríguez, R. U. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i33.5502
Bock, S., Neumann‐Böhme, S., & Steinorth, P. (2025) · BMC Public Health · doi:10.1186/s12889-025-22471-3 · Cited by 1
“The necessity for regular booster shots only became evident over time after promising results on vaccine efficiency at the end of 2021 [12].”
Synthesis of 1,3,5‐Triazine‐Indole Conjugates as Broad‐Spectrum Coronavirus Entry Inhibitors
Asghar, S., Persoons, L., Smolders, Y., Willems, N., Daelemans, D., Jonghe, S. D., Al-Masoudi, N. A., & Hameed, S. (2026) · ChemMedChem · doi:10.1002/cmdc.70434
“Vaccines [11 – 15] and neutralizing antibodies [16 – 18] targeting SARS-CoV-2 spike glycoprotein remain central to COVID-19 prevention strategies, yet the emergence of viral variants such as Delta and Omicron has markedly compromised vaccine efficacy.”
Management of Cancer During the COVID-19 Pandemic: The Rewritten Rules
Dosso, S. D., & Vannelli, A. (2021) · healthbook TIMES Oncology Hematology · doi:10.36000/hbt.oh.2021.09.043
COVID-19 Vaccine Survey among Healthcare Workers. A Community Experience.
Theophilus, N., Ríos‐Bedoya, C. F., & Bachuwa, G. I. (2022) · Spartan Medical Research Journal · doi:10.51894/001c.35628 · Cited by 1
NEURO-COVAX: An Italian Population-Based Study of Neurological Complications After COVID-19 VaccinesPreprint
Salsone, M., Signorelli, C., Oldani, A., Patone, M., Alberti, V. F., Castronovo, V., Mazzitelli, S., Minerva, M., & Ferini‐Strambi, L. (2022) · Research Square · doi:10.21203/rs.3.rs-1978727/v1
COVID-19 Pandemic and Next Pandemic Preparedness of Long-term Care Hospitals and Facilities
Chang, K. (2025) · Korean Journal of Healthcare-Associated Infection Control and Prevention · doi:10.14192/kjicp.2025.30.2.105
Rapid expression of therapeutic antibodies in mammalian cells via mRNA transfection
Chavalparit, T., Barry, C. P., Gunter, H., Gillard, M., Mercer, T. R., & Marcellin, E. (2025) · mAbs · doi:10.1080/19420862.2025.2599584 · Cited by 2
Shimada, N., Sugawa, S., Murakami, S., Shinoda, M., Ota, S., Morikawa, M., Takei, H., Serizawa, Y., Takahashi, H., Toyama‐Kousaka, M., et al. (2024) · Vaccine X · doi:10.1016/j.jvacx.2024.100518
“In a clinical trial involving 43,548 participants, BNT162b2 was found to be 95 % effective in preventing COVID-19 [3].”
BackgroundChen, P., Bergman, P., Blennow, O., Hansson, L., Mielke, S., Nowak, P., Gao, Y., Söderdahl, G., Österborg, A., Smith, C. I. E., et al. (2026) · EBioMedicine · doi:10.1016/j.ebiom.2026.106279
Equality and the Intersectionality of Biological Aging
Farrelly, C. (2026) · Oxford University Press eBooks · doi:10.1093/9780197830062.003.0007
Kersebaum, D., Sendel, M., Fabig, S., Sachau, J., Lassen, J., Rehm, S., Forstenpointner, J., Rümenapp, J., Vollert, J., Hüllemann, P., et al. (2022) · Medicine · doi:10.1097/md.0000000000032054
“Probably the most dramatic advance was the development of promising vaccine candidates in record time.[1,2] Among the multitude of pandemic- and quarantine-associated aspects that are being investigated and discussed, the psychological and social impacts are major.”
BackgroundShall we count the living or the dead?Preprint
Huitfeldt, A., Fox, M. P., Murray, E. J., Hróbjartsson, A., & Daniel, R. (2021) · arXiv (Cornell University) · doi:10.48550/arxiv.2106.06316 · Cited by 17
“To illustrate, we will consider the Pfizer BNT162b2 mRNA Covid-19 Vaccine, which has been shown to have an effectiveness of 95 percent[48] at preventing Covid-19, corresponding to θ = 0.”
MethodKnowledge, Attitude, and Perception of Youth Population in Indonesia toward COVID-19 Vaccination
Nurfaizi, A., Afgriyuspita, L. S., Suasti, N. M. A., et al. (2023) · Asian Journal of Health Research · doi:10.55561/ajhr.v2i1.63
Su, J., Hamway, Y., Mistretta, D., Liao, B., Ma, Z., Schluckebier, J., Xie, Z., Polezhaeva, O., Jradi, W., Braun, S., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1827532 · Cited by 1
Martin, A. L., Cotterell, J., Buick, K. H., Bird, T. W., Kuang, J., Palmer, O. R., Mason, N. C., White, L. G., Draper, S. L., Foster, A. J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.06.11.731499
“After demonstrating rapid scalability and high efficacy against SARS-CoV-2 10–12 , mRNA vaccines have continued to transform the vaccinology landscape, across both infectious diseases 13,14 and cancer 15,16 .”
Colangeli, L., Aprile, G., Carcone, C., D’Adamo, M., Medda, E., Sbraccia, P., & Guglielmi, V. (2023) · Internal and Emergency Medicine · doi:10.1007/s11739-022-03185-5
LES VACCINS anti-SARS-Cov-2 et LES QUESTIONS QU'ILS EVOQUENTPreprint
Labdi, A. (2021) · OSF Preprints (OSF Preprints) · doi:10.31219/osf.io/4x763
The anti SARS-Cov-2 Vaccines And The Questions They RaisePreprint
Labdi, A. (2021) · doi:10.31219/osf.io/tvuqj
Efficacité des vaccins contre la Covid-19 : ce que signifient les statistiques… ou pas
Froda, S., & Larribe, F. (2021) · doi:10.64628/aap.qegphgwwh
Clar, M., Walker, A., & Solomon, P. (2023) · Springer eBooks · doi:10.1007/978-3-030-01782-8_126-1
Deployment of COVID-19 diagnostic testing: challenges and key considerations for the futurePreprint
Möckel, M., Baldanti, F., Ganguly, N. K., Wang, G., O'Neil, L. A., Renz, H. E., Ferreira, C. E. D. S., Tateda, K., & Pol, B. J. V. D. (2021) · doi:10.22541/au.161738497.71208486/v1
Junkins, E. J., Chehab, S., Lee, K. M. N., & Clancy, K. B. H. (2023) · doi:10.31234/osf.io/vs2uf
González-Sánchez, Ó. A., González-Ortiz, L. J., Sánchez-Peña, M. J., & Pulido, H. G. (2025) · Vaccines · doi:10.3390/vaccines13040363
“…assuming that effectiveness is maintained constant for considerable periods, the confirmed cases during the whole study are globally counted to calculate a single effectiveness value with a confidence interval assumed to be valid for the entire study period, highly affecting the precision [3–9].”
InfluentialÇetin, M., & Beyhan, S. (2022) · Studies in computational intelligence · doi:10.1007/978-3-031-04597-4_7
Progress in the Application of Gold Nanoparticles in Viral Diseases
温, 一. (2024) · Hans Journal of Nanotechnology · doi:10.12677/nat.2024.141001
Prevalence of COVID-19 vaccines side effects among health care workers in Kirkuk City, Iraq
Mehammed-Ameen, O. H., Hasan, N. N., & Ismael, Z. A. (2024) · International Journal of Public Health Science (IJPHS) · doi:10.11591/ijphs.v13i3.23988
Kumar, S. (2026) · Springer eBooks · doi:10.1007/978-981-95-7688-3_5
Reactivación del virus varicela zóster tras la vacunación contra la COVID-19
López, J. V., & Rodríguez-Saldaña, J. (2022) · Piel · doi:10.1016/j.piel.2022.03.007
The Should Healthcare Facilities Mandate COVID-19 Vaccination of its Employees?
Rao, S., & Singh, M. (2021) · DHR Proceedings · doi:10.47488/dhrp.v1is4.17
Callanan, R., Deasy, C., Slowey, J., Brien, R. O., Dunphy, M., Dasari, K., Brennan, T., Walsh, S., Gilmartin, S., Sullivan, I. O., et al. (2021) · Emergency Medicine Journal · doi:10.1136/emermed-2021-211704
Corsini, C. A., Campos, G. R. F., Martins, P. F. D. S., Filgueiras, P. S., Lima, A. E. D. S., Gomes, S. V. C., Curimbaba, C., Lorencini, D. A., Morandi, E., da Silva, V. M., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1589733 · Cited by 1
COVID-19 Considerations in Heart Transplantation
Peled, Y. (2025) · Springer eBooks · doi:10.1007/978-3-031-88290-6_17
Saw, P. E. (2021) · BIO Integration · doi:10.15212/bioi-2021-0008
“The phase III trial results of the mRNA vaccine BNT162b2 developed by Pfizer and BioNTech was published online on December 10, 2020, in the New England Journal of Medicine [5].”
BackgroundInfluentialSellaro, F., Pernetti, R., Candura, S. M., et al. (2025) · Safety · doi:10.3390/safety11010016
COVID-19: Vaccines on Their Marks
Jagtiani, E., & Vithlani, D. (2021) · The Bombay Technologist · doi:10.36664/bt/2021/v68i1/162888
Hale, K. L. E., McCarthy, H. O., & McLaughlin, M. (2026) · Chemistry - A European Journal · doi:10.1002/chem.202502321
Suzuki-Okutani, M., Okamura, S., Tanggis, et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.03.582873
Nair, P. K., Koh, K. E., Bede, C. Y., Natasha, L. A. R., Mahanama, M. D., Kyaw, T. M., Soe, H. H. K., Moe, S., Rahaman, K. M., & Htay, M. N. N. (2023) · Asian Pacific Journal of Tropical Medicine · doi:10.4103/1995-7645.380723
Shankar, S., Beckett, J. G., Tipton, T., Ogbe, A., Kasanyinga, M., Dold, C., Lumley, S., Dengu, F., Rompianesi, G., Elgilani, F., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3941809
Haldar, R., Halder, P., & Mahanayak, B. (2026) · Discover Public Health · doi:10.1186/s12982-026-01657-z
“These vaccines were effective against earlier variants such as Alpha, Gamma, and Delta but indicates limited protection against Omicron unless used in heterologous booster regimens [54, 55].”
mRNA lipid nanoparticle vaccines: current status, challenges and future prospects
吴志能, Lou, J., Cheng, Y., Li, M., Wang, Z., Liu, N., Gao, X., Zheng, A., & Zhang, H. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00600-7
“…initially deployed against COVID-19, faced critical limitations, including formulation instability and stringent cold-chain requirements (e.g., storage at − 80 °C or − 20 °C), waning immunity, and the risk of aberrant inflammatory responses that compromise their overall efficacy and safety [19–21].”
Moyet, J., Helle, F., Bourdenet, G., Joseph, C., Gubler, B., Brochot, É., & Bloch, F. (2021) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/ggi.14289
Psoriatic arthritis and psoriasis in the era of COVID-19
Athanassiou, P., Athanassiou, L., & Kostoglou‐Athanassiou, I. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18566-3.00038-4
5 factors that could dictate the success or failure of the COVID-19 vaccine rollout
Bridle, B. W. (2021) · The Conversation · doi:10.64628/aam.spkjkhnr6
Decoding trends in mRNA vaccine research: A comprehensive bibliometric study
Zhang, C., Wang, Y., Peng, J., Wen, X., Zhang, Y., Li, K., Du, H., & Hu, X. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2355037 · Cited by 4
Sularea, V. M., Townsend, L., Reid, C., Atanasescu, A. V., Dyer, A. H., Giangrazi, F., Lawrence, R. R., Sivan, M., Moran, B., Doherty, D. G., et al. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaf447 · Cited by 1
Teo, S. P. (2021) · Vaccine Research · doi:10.52547/vacres.8.2.1
“2 BioNTech (BNT162b2) [9], Moderna (mRNA-1272) [10], Astra Zeneca (ChAdOx1 nCoV-19) [11], Janssen (Ad26.”
BackgroundAlexandre, M., Marlin, R., Bossevot, L., Cavarelli, M., Dereuddre‐Bosquet, N., Relouzat, F., Centlivre, M., Grand, R. L., Thiébaut, R., Lévy, Y., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.01.15.699647
COVID-19 Vaccinations: Information for Providers
Hanna, K. (2021) · Graduate Medical Education Research Journal
Advances in FRET-based Applications Within Biomimicking Molecular Self-assemblies
Chatterjee, A., & Purkayastha, P. (2026) · Journal of Fluorescence · doi:10.1007/s10895-026-04883-5
Metadata
- Authors
- Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., Bailey, R., Swanson, K. A., Roychoudhury, S., Koury, K., Li, P., Kalina, W. V., Cooper, D., Frenck, R. W., Hammitt, L. L., Türeci, Ö., Nell, H., Schaefer, A., Ünal, S., Tresnan, D. B., Mather, S., Dormitzer, P. R., Şahin, U., Jansen, K. U., & Gruber, W. C.
- Affiliations
- Cincinnati Children's Hospital Medical Center (US)
- From Fundacion INFANT (F.P.P.) and iTrials-Hospital Militar Central (G.P.M.), Buenos Aires; State University of New York, Upstate Medical University, Syracuse (S.J.T.), and Vaccine Research and Development, Pfizer, Pearl River (J.A., A.G., K.A.S., K.K., W.V.K., D.C., P.R.D., K.U.J., W.C.G.) — both in New York; Vaccine Research and Development, Pfizer, Hurley, United Kingdom (N.K., S.L., R.B.); Vaccine Research and Development (J.L.P., P.L.) and Worldwide Safety, Safety Surveillance and Risk Management (S.M.), Pfizer, Collegeville, PA; Associação Obras Sociais Irmã Dulce and Oswaldo Cruz Foundation, Bahia (E.D.M.), and Centro Paulista de Investigação Clinica, São Paulo (C.Z.) — both in Brazil; Global Product Development, Pfizer, Peapack, NJ (S.R.); Cincinnati Children’s Hospital, Cincinnati (R.W.F.); Johns Hopkins Bloomberg School of Public Health, Baltimore (L.L.H.); BioNTech, Mainz (ÖT., U.Ş.), and Medizentrum Essen Borbeck, Essen (A.S.) — both in Germany; Tiervlei Trial Centre, Karl Bremer Hospital, Cape...
- Corresponding author
- Absalon, Judith
- ORCID
- Polack, Fernando P.
- Thomas, Stephen J.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Moreira, Edson D.
- Zerbini, Cristiano
- Swanson, Kena A.
- Roychoudhury, Satrajit
- Li, Ping
- Cooper, David
- Frenck, Robert W.
- Hammitt, Laura L.
- Türeci, Özlem
- Ünal, Serhat
- Mather, Susan
- Dormitzer, Philip R.
- Şahin, Uğur
- Jansen, Kathrin U.
- Gruber, William C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-12-31
- Volume
- 383
- Issue
- 27
- Pages
- 2603-2615
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7745181
- OpenAlex
- W3111255098
- Cited by
- 14,592
- References
- 8
- Citations by year
- 2026: 756 · 2025: 1216 · 2024: 1543 · 2023: 2310 · 2022: 4192 · 2021: 4494 · 2020: 77
- FWCI
- 362.87
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Arca - Repositório Institucional da Fiocruz (submittedVersion, other-oa)
- Repositorio Académico UPC (Universidad Peruana de Ciencias Aplicadas) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, other-oa)
- Funders
- BioNTech and Pfizer
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- BNT162b2, COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, vaccine efficacy, vaccine safety, severe COVID-19 prevention, two-dose regimen, serious adverse events, subgroup analysis, immunogenicity, immunocompromised patients, pregnant and lactating women
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, BNT162 Vaccine, Adolescent, Adult, Aged, Fatigue, Female, Headache, Humans, Immunization, Secondary, Male, Middle Aged, Vaccines, Synthetic, Single-Blind Method, Treatment Outcome, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.